Wyeth Prevnar Coverage In Managed Care Tops 90%; Sales Top $200 Mil.
Executive Summary
Wyeth-Ayerst expects the pneumococcal conjugate vaccine Prevnar to reach "full penetration of the U.S. market" during 2001.
You may also be interested in...
Wyeth Prevnar Vaccine Shortage Will Continue Through December, CDC Says
Wyeth-Lederle's Prevnar pneumococcal conjugate vaccine shortage is expected to continue through December, the Centers for Disease Control & Prevention said.
Wyeth Prevnar Vaccine Shortage Will Continue Through December, CDC Says
Wyeth-Lederle's Prevnar pneumococcal conjugate vaccine shortage is expected to continue through December, the Centers for Disease Control & Prevention said.
AHP Sets Redux Liability Cost At $12 Bil.: 25% More Than Price Of Cyanamid
American Home Products' latest cost estimate for the Redux liability case is approximately 25% higher than the cash payment AHP made in 1994 to acquire American Cyanamid.